Introduction
============

In 2016, 39% of the world's adult population was overweight, and 13% was obese ([@B1]). In the context of fetal programming, it is well-accepted that an obesogenic intrauterine environment has long-lasting effects on the fetus. A high maternal body mass index (BMI) is a risk factor for adverse birth outcomes and infant death ([@B6]; [@B30]), and offspring of obese mothers have a higher risk of developing obesity, diabetes, and cardiovascular diseases in later life ([@B12]).

Recent advances in molecular technologies suggest that the placenta is the master regulator of the fetal environment, representing a higher level of control of fetal programming compared to other tissues ([@B26]). The placenta plays a critical role in nutrient and waste transfer, endocrine secretion, immunological protection, and xenobiotic detoxification ([@B7]). In addition, the placenta can undergo major structural and functional adaptations in order to protect the fetus from environmental stressors. However, if the organ's capacity for adaptation is exceeded or if placental function is impaired, the intrauterine environment might be perturbed and fetal development could be affected, with potential adverse consequences for later-life health.

Despite the central role of the placenta in fetal programming, only a limited number of studies have assessed the genome-wide effect of maternal weight on the human placental transcriptome ([@B42]; [@B4]). Studies assessing placental transcriptome profiles related to fetal growth mostly focused on intrauterine growth restriction ([@B35]; [@B29]), often in the context of pre-eclampsia ([@B25]), whereas genome-scale studies linking placental gene expression with excessive fetal growth are scarce ([@B43]; [@B3]; [@B45]; [@B46]). Most of the previous studies used a univariate differential expression analysis approach, typically comparing a limited number of adverse with normal phenotypes. Methods taking into account the correlations between genes, such as weighted gene co-expression network analysis (WGCNA) ([@B55]), have been proposed to facilitate the identification of genes with similar functions, thereby providing a systematic understanding of molecular mechanisms underlying biological processes.

The identification of a placental gene expression signature related to maternal BMI as well as fetal growth may provide new insights into the molecular mechanisms underlying the intrauterine programming of metabolic health. To the best of our knowledge, no study so far has looked at the overlap between placental transcriptome profiles related to maternal pre-pregnancy BMI and fetal growth. Using WGCNA, we identified placental co-expressed gene modules and hub genes associated with both maternal pre-pregnancy BMI and weight of the newborn and we investigated whether these modules and hub genes mediated the association between pre-pregnancy BMI and newborn weight.

Materials and Methods {#s1}
=====================

Study Population
----------------

Within the framework of the ongoing Belgian birth cohort ENVIR*ON*AGE (ENVIRonmental influence *ON* early AGEing), mother-newborn pairs were recruited upon arrival for delivery at the East-Limburg Hospital in Genk, Flanders ([@B19]). Procedures were approved by the Ethical Committee of Hasselt University and the East-Limburg Hospital and recruitment was carried out according to the Helsinki declaration. Mothers without a planned cesarean section and who were able to fill out a questionnaire in Dutch, were eligible for participation. For this study, we used a subsample of 195 mother-newborn pairs recruited between January 2014 and April 2017. Samples with missing covariate information (*n* = 5), a birth weight below 1000 g (*n* = 1), or low quality of extracted RNA (RNA integrity number below 6) (*n* = 6), were excluded from the analysis, resulting in a final sample size of 183.

Information on variables such as gestational age, birth weight, maternal pre-pregnancy weight, height, and weight before delivery were retrieved from the medical records of the hospital. Gestational age was estimated based on the mother's last menstrual period in combination with ultrasound data. Maternal height and weight were measured at the first antenatal visit (weeks 7--9 of gestation) wearing no shoes and light clothes. Pre-pregnancy BMI was calculated as weight in kilograms divided by the square of height in meters and categorized into four groups: underweight (below 18.5 kg/m^2^), normal weight (18.5--24.9 kg/m^2^), overweight (25.0--29.9 kg/m^2^), and obese (30.0 kg/m^2^ or above). Maternal pregnancy weight gain was calculated from the pre-pregnancy weight and the weight measured on admission to the delivery ward. Low birth weight was defined as a birth weight below the 10^th^ percentile of the sample (2643 g), and high birth weight as a birth weight above the 90^th^ percentile (3963 g).

Detailed information about socio-demographic and lifestyle factors such as maternal age, smoking status during pregnancy, parity, and newborn's ethnicity were obtained from questionnaires. Maternal smoking status was defined as never smokers, past smokers (quit smoking cigarettes before pregnancy), and current smokers (smoked cigarettes during pregnancy). Parity was categorized into 1, 2, and ≥3 children. Classification of ethnicity is based on the native country of the neonates' grandparents as either European (at least two grandparents were European) or non-European (at least three grandparents were of non-European origin).

Sample Collection and RNA Isolation
-----------------------------------

Placental tissue was collected within 1 h after delivery. Four standardized biopsies were taken from the fetal side, at fixed locations across the middle point of the placenta around 4 cm distance from the umbilical cord ([@B19]). The collected biopsies were stored in RNA *later* (Thermo Fisher Scientific, Waltham, MA, United States) at 4°C for at least 12 h and maximally 24 h, followed by storage at -20°C. Total RNA was extracted from one placental tissue biopsy using the miRNeasy mini kit (Qiagen, Venlo, Netherlands) according to the manufacturer's protocol. RNase-Free DNase treatment was performed on RNA samples according to the manufacturer's instructions (Qiagen, Venlo, Netherlands). RNA quantity and purity was assessed by spectrophotometry (Nanodrop 1000, Isogen Life Science, De Meern, Netherlands) and RNA integrity by Agilent 2100 Bioanalyzer (Agilent Technologies, Amstelveen, Netherlands).

Microarray Preparation, Hybridization, and Preprocessing
--------------------------------------------------------

0.2 μg total RNA was used to synthesize fluorescent cyanine-3-labeled cRNA following the Agilent one-color Quick-Amp labeling protocol (Agilent Technologies) and hybridized onto Agilent Whole Human Genome 8 × 60 K microarrays. Microarray signals were detected using the Agilent DNA G2505C Microarray Scanner (Agilent Technologies). Scan images were converted into TXT files using the Agilent Feature Extraction Software (Version 10.7.3.1, Agilent Technologies, Amstelveen, Netherlands). An in-house developed quality control pipeline in R software was used to preprocess raw data as follows: local background correction, omission of controls, flagging of bad spots and spots with too low intensity, log2 transformation and quantile normalization using arrayQC. More information about the flagging and the R-scripts of the pipeline are available at <https://github.com/BiGCAT-UM/arrayQC_Module>. Further preprocessing included removal of probes showing \> 30% flagged data, merging of replicate probes based on the median, and imputation of missing values by means of K-nearest neighbor imputation (*K* = 15). Batch effects were corrected for by using an empirical Bayes method (ComBat) ([@B20]). For genes with multiple probes, the probe with the largest interquartile range was selected. From the resulting 18,847 probes, only those with expression levels above 6 (in the log2 scale) in a minimum of 30 samples were kept, leaving 14,040 genes for further analysis. Data are available via NCBI Gene Expression Omnibus (GEO) with the Accession No. [GSE128381]{.ul}.

Statistical Analysis
--------------------

The association between maternal pre-pregnancy BMI (as a continuous and as categorical variable) and birth weight was assessed through a linear regression model adjusting for date of delivery, newborn sex, gestational age, ethnicity, parity, maternal age, maternal smoking, and weight gain during pregnancy.

First, we assessed the associations of transcripts levels (of 14,040 genes) with maternal pre-pregnancy BMI and with birth weight using univariate models, correcting for the same variables as above. We adjusted for multiple testing by controlling the Benjamini--Hochberg false discovery rate (FDR) at 5%.

Then we constructed a gene co-expression network by using the WGCNA package ([@B27]) in R, following the general WGCNA guidelines ([@B53]). Briefly, pairwise Pearson correlation coefficients between all (*n* = 14,040) genes were calculated to generate a signed similarity. A weighted adjacency matrix was obtained by raising the signed similarity matrix to a power β, which was set to 14 after a sensitivity analysis of scale-free topology (*R*^2^ \> 0.9). The adjacency matrix was then converted to a topological overlapping matrix (TOM) network, which was used as input for a hierarchical clustering analysis. Finally, modules were identified by implementing a dynamic tree cutting algorithm on the TOM-based dendrogram, using the parameters deepSplit = 2 and minClusterSize = 30. The resulting gene clusters (modules) get a color name as identifier, with *gray* denoting background genes outside of modules. The module eigengene (ME), calculated as the eigenvector associated with the first principal component of the expression matrix, serves as a summary measure for the module. A cut height of 0.35 was used to merge modules with a correlation between MEs of 0.65 or greater.

To identify gene clusters associated with traits such as maternal pre-pregnancy BMI, we used linear regression models treating the MEs as dependent variables and the traits as independent variables, correcting for the same variables as above. Maternal BMI and newborn birth weight were modeled as continuous and as categorical variables in order to capture potential non-linear associations. Normal pre-pregnancy BMI and normal birth weight were used as reference categories. Regression coefficients were expressed as partial Pearson correlations (with *P*-values), using the ppcor package in R ([@B24]). Modules of interest were those that were significantly correlated with one of the maternal BMI variables (continuous variable or one of the BMI categories) as well as with one of the birth weight variables (continuous variable or low birth weight or high birth weight). The *P*-value cut-off for selecting modules of interest was set at 0.1.

Modules of interest were further characterized by gene ontology (GO) and pathway enrichment analyses. Overrepresented GO biological processes and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways inside each module were identified by using WebGestalt ([@B54]; [@B51]), considering a FDR \< 0.05 as the criterion for statistical significance after Benjamini--Hochberg correction for multiple testing. The REVIGO tool ([@B48]) was used to filter out redundant GO terms and to visualize enrichment analysis results.

For the modules of interest, highly connected intramodular genes (hub genes) related to maternal pre-pregnancy BMI and birth weight were selected based on two criteria: (1) the module membership (MM), calculated as the Pearson correlation between the expression of a gene and the ME, and (2) the significance of the partial Pearson correlations between expression levels of individual genes and the traits of interest \[BMI, BMI categories (underweight, overweight, obese), birth weight, birth weight categories (low and high birth weight)\]. Partial Pearson correlations (with *P*-values) were obtained as described for the MEs and were corrected for the same set of variables. Hub genes were defined as genes with \|MM\| ≥ 0.8 and *P* \< 0.05 for at least one maternal BMI variable and at least one birth weight variable. In separate sensitivity analyses, associations of traits of interest with MEs and hub genes were tested after excluding non-European newborns (*n* = 26), mothers with gestational diabetes (*n* = 6), and mothers with gestational hypertension (*n* = 8) from the study population.

To investigate expression of identified modules and genes as a potential molecular link between maternal pre-pregnancy BMI and newborn birth weight, we performed mediation analyses with pre-pregnancy BMI as independent causal variable and birth weight as outcome. The mediating effect of modules and hub genes was tested using the default quasi-Bayesian Monte Carlo method and bootstrap simulation (10000 simulations) from the R mediation package ([@B49]).

Results
=======

General characteristics of our study population (*n* = 183) are provided in [Table 1](#T1){ref-type="table"}. 4.4% of the mothers was underweight, 26.2% was overweight and 14.8% was obese before pregnancy. Our study population included 24 (13.1%) preterm births (gestational age below 37 weeks). Most of the low birth weight babies (16 out of 19) were preterm and all high birth weight babies had a gestational age above 38 weeks. Our sample was representative for all deliveries in Flanders ([@B8]) with respect to newborn birth weight \[average (10^th^--90^th^ percentile) = 3328 (2643--3963) gram compared to 3360 (2740--3965) gram\] and characteristics such as maternal age, parity, sex, and ethnicity ([Supplementary Table S1](#SM1){ref-type="supplementary-material"}).

###### 

Characteristics of study population (*n* = 183).

  Characteristics                   Mean ± SD/frequency (%)
  --------------------------------- -------------------------
  **Mother**                        
  Age, *years*                      29.9 ± 4.4
  Pre-pregnancy BMI, *kg/m^2^∗^^*   25.0 ± 5.2
      Underweight                   8 (4.4)
      Normal weight                 100 (54.6)
      Overweight                    48 (26.2)
      Obese                         27 (14.8)
  Gestational weight gain, *kg*     13.5 ± 5.7
  Smoking status                    
      Never-smoker                  123 (67.2)
      Past-smoker                   46 (25.2)
      Current smoker                14 (7.6)
  Parity                            
      *1*                           89 (48.6)
      *2*                           71 (38.8)
      *≥3*                          23 (12.6)
  Gestational diabetes              6 (3.3)
  Gestational hypertension          8 (4.4)
  **Newborn**                       
  Boys                              95 (51.9)
  Gestational age, *weeks*          38.9 ± 2.1
  Birth weight, *g*^†^              3,328 ± 532
      Low                           19 (10.0)
      Normal                        145 (80.0)
      High                          19 (10.0)
  European ethnicity^\#^            157 (85.8)

∗

Pre-pregnancy BMI was coded as underweight (below 18.5 kg/m

2

), normal weight (18.5--24.9 kg/m

2

), overweight (25.0--29.9 kg/m

2

), and obese (30.0 kg/m

2

or above).

†

Low birth weight was defined as a birth weight below the 10

th

percentile of the sample (\<2643 g), normal weight as a birth weight between the 10

th

and 90

th

percentile (2643--3963 g) and high birth weight as a birth weight above the 90

th

percentile (\>3963 g).

\#

Newborns were classified as European when at least two grandparents were European, and non-European when at least three grandparents were of non-European origin

.

A histogram of birth weight and a scatterplot of birth weight versus maternal pre-pregnancy BMI with unadjusted and adjusted regression lines are presented in [Supplementary Figure S1](#SM1){ref-type="supplementary-material"}. Birth weight was positively associated with maternal pre-pregnancy BMI and was estimated to be 13.3 g (95% confidence interval \[CI\]: 3.0, 23.6 g) higher for a 1 kg/m^2^ higher maternal BMI. Compared with newborns of normal weight mothers, birth weight of newborns from underweight and overweight mothers was not significantly different (-46.7 g \[95% CI: -305.4, 212.0 g\] and 54.6 g \[95% CI: -68.4, 177.7 g\], respectively), but birth weight of those from obese mothers was significantly higher (202.2 g, 95% CI: 45.4, 359.0 g). The estimated increase in birth weight for a 1 kg increase in maternal weight gain during pregnancy was 16.7 g (95% CI: 7.2, 26.2 g).

Univariate Models
-----------------

In models assessing the associations between transcripts levels and maternal pre-pregnancy BMI or birth weight, none of 14,040 genes survived Benjamini--Hochberg correction for multiple testing. Unadjusted *P*-values for maternal BMI and birth weight were \< 0.05 for 832 and 745 genes respectively, with an overlap of 101 genes ([Supplementary Table S2](#SM1){ref-type="supplementary-material"}). For all of the overlapping genes, the direction of the association with maternal BMI and with birth weight was consistent, with 75 of them being upregulated in association with both variables and 26 being downregulated in association with both.

Weighted Gene Co-expression Network Analysis
--------------------------------------------

Weighted gene co-expression network analysis identified 17 co-expressed gene modules ([Supplementary Figure S2](#SM1){ref-type="supplementary-material"}). The *gray* module, consisting of genes not attributed to any module, contained 9 genes. The size of other modules ranged from 48 to 5298 genes. A heatmap of the module-trait associations, presenting the partial Pearson correlations between MEs and traits, is shown in [Figure 1](#F1){ref-type="fig"}. Modules found to be associated (*P* \< 0.1, corresponding to *r* ≥ 0.13) with at least one of the maternal BMI variables and at least one of the birth weight variables were *darkgray* (*n* = 69 genes), *darkred* (*n* = 1091 genes), *gray60* (*n* = 204 genes), and *lightgreen* (*n* = 451 genes). The *darkgray* module showed a positive correlation with maternal pre-pregnancy BMI (*r* = 0.15, *P* = 0.044) and a negative correlation with low birth weight (*r* = -0.19, *P* = 0.011). The *darkred* module was positively associated with maternal BMI (*r* = 0.14, *P* = 0.077), with maternal obesity (*r* = 0.15, *P* = 0.06), and with birth weight (*r* = 0.13, *P* = 0.098). Also *gray60* was positively associated with maternal BMI (*r* = 0.20, *P* = 0.008), maternal obesity (*r* = 0.18, *P* = 0.015), and birth weight (*r* = 0.14, *P* = 0.076). The *lightgreen* module showed a negative correlation with maternal underweight (*r* = -0.13, *P* = 0.079), as well as with high birth weight (*r* = -0.15, *P* = 0.056).

![Associations between module eigengenes (ME, in rows) and traits (in columns). Colors indicate the strength and the direction of the correlation according to the color legend. The numbers represent the partial Pearson correlations with corresponding *P*-values in parenthesis (only those with *P* \< 0.1 are shown). Partial correlations were obtained from models adjusted for date of delivery, newborn sex, gestational age, ethnicity, parity, maternal age, maternal smoking, and weight gain during pregnancy. Modules found to be associated (*P* \< 0.1, corresponding to *r* ≥ 0.13) with at least one of the maternal BMI variables and at least one of the birth weight variables were *darkgray*, *darkred*, *gray60*, and *lightgreen*. As the correlations observed in the *lightgreen* module were driven by one specific observation, only the *darkgray*, *darkred*, and *gray60* modules were considered for further analyses.](fgene-10-00354-g001){#F1}

We checked the robustness of the above associations by excluding underweight mothers with a high birth weight baby (*n* = 1) and overweight mothers with a low birth weight baby (*n* = 4) from the partial correlation analysis (our sample did not contain obese mothers with a low birth weight baby). We noticed that the correlations observed in the *lightgreen* module were driven by the one underweight mother with a high birth weight baby (both *P* \> 0.1 after excluding this observation from the analysis). Exclusion of this particular observation did not alter the associations observed in the *darkgray*, *darkred*, and *gray60* modules, neither did the exclusion of the four overweight mothers having a newborn with low birth weight. Consequently, only the *darkgray*, *darkred*, and *gray60* modules were considered for further analyses.

GO and Pathway Enrichment Analyses
----------------------------------

In the modules *darkgray*, *darkred*, and *gray60*, we found 7, 110, and 56 enriched GO biological processes ([Supplementary Table S3](#SM1){ref-type="supplementary-material"}) and 0, 22, and 7 enriched KEGG pathways ([Supplementary Table S4](#SM1){ref-type="supplementary-material"}), respectively. Redundant GO terms were removed by REVIGO and results are summarized by means of a treemap ([Figure 2](#F2){ref-type="fig"}). The five non-redundant GO biological processes in the *darkgray* module were response to fungus, cell killing, modification of morphology or physiology of other organism, myeloid cell differentiation, and response to inorganic substance, but no enriched KEGG pathways were found. The *darkred* and *gray60* modules were close to each other in the hierarchical clustering ([Supplementary Figure S2](#SM1){ref-type="supplementary-material"}), which is reflected in the overlap in enriched GO terms (28 common processes). Most of the biological processes in the *darkred* module were related to organ and tissue development (35 out of 76 enriched processes), with blood vessel morphogenesis as top GO term (lowest FDR). The most enriched KEGG pathway was vascular smooth muscle contraction, and other pathways involved signal transduction (six pathways), endocrine system (four pathways), cancer (three pathways), and environmental adaptation (two pathways) ([Figure 3](#F3){ref-type="fig"}). Also in the *gray60* module, the majority of GO biological processes (37 out of 47) were related to organ and tissue development, with extracellular structure organization as the most enriched process. The *gray60* module contained seven enriched KEGG pathways, including PI3K-Akt signaling, focal adhesion, protein digestion and absorption, and extracellular matrix receptor interaction.

![Treemap of GO biological processes enriched in the placental microarray modules of interest. REVIGO was used to remove redundant GO terms and to join the cluster representatives (the single rectangles) into superclusters (represented by different colors). The size of each rectangle reflects the FDR value of the GO term (larger for lower FDR).](fgene-10-00354-g002){#F2}

![Treemap of KEGG pathways enriched in the placental microarray modules of interest. The KEGG hierarchy was used to join the pathways (the single rectangles) into superclusters (represented by different colors). The size of each rectangle reflects the FDR value of the pathway (larger for lower FDR).](fgene-10-00354-g003){#F3}

Intramodular Hub Genes
----------------------

Hub genes for the modules of interest were selected according to the criteria: \|MM\| ≥ 0.8 and significantly (*P* \< 0.05) correlated with at least one maternal BMI variable and at least one birth weight variable ([Table 2](#T2){ref-type="table"}). Actual *P*-values of the partial correlations with BMI and birth weight variables are presented in [Supplementary Table S5](#SM1){ref-type="supplementary-material"}. In the *darkgray* module, we found five hub genes positively correlated with maternal BMI and negatively correlated with low birth weight: *XLOC_000346*, *AHSP*, *XLOC_013489*, *SLC4A1*, and *HBQ1*. The hub genes in the *darkred* module (*FZD4*, *CDC42EP2*, *COL15A1*, *TBXA2R*, *EHD2*, *GPR124*, *VIM*, *EFEMP2*, and *TBX2*) and in the *gray60* module (*COL8A2*, *MATN2*, *KANK2*, *COL6A1*, *TRPC1*, *COL16A1*, *COL3A1*, *RUNX1T1*, *AEBP1*, *COL1A1*, and *RGS11*) showed a positive correlation with maternal BMI and/or obesity, as well as with birth weight. *TRPC1* and *COL16A1* in the *gray60* module were also negatively correlated with maternal underweight. Fourteen of these genes (*FZD4*, *COL15A1*, *TBXA2R*, *EHD2*, *GPR124*, *COL8A2*, *MATN2*, *COL6A1*, *TRPC1*, *COL16A1*, *COL3A1*, *RUNX1T1*, *AEBP1*, and *COL1A1*) were also picked up in the univariate models (unadjusted *P*-values for maternal BMI and birth weight \< 0.05), but FDR values were \> 0.05.

###### 

Hub genes for the modules of interest, defined as \|MM\| ≥ 0.8 and a significant partial correlation with at least one maternal BMI variable and at least one birth weight variable.

                                                                                                               Partial correlation                                             
  ----------------------- ------------------------------------------------------------------ ------ ---------- --------------------- ------- ---------- ---------- ----------- -------
  ***Darkgray* module**                                                                                                                                                        
  *XLOC_000346*                                                                              0.85   0.17\*     -0.02                 0.02    0.16\*     0.04       -0.16\*     0.02
  *AHSP*                  Alpha hemoglobin stabilizing protein                               0.88   0.17\*     -0.05                 0.00    0.12       0.04       -0.18\*     -0.02
  *XLOC_013489*                                                                              0.92   0.17\*     -0.01                 0.01    0.14       0.02       -0.18\*     -0.05
  *SLC4A1*                Solute carrier family 4 member 1 (Diego blood group)               0.91   0.15\*     -0.04                 -0.01   0.12       0.07       -0.19\*     -0.04
  *HBQ1*                  Hemoglobin subunit theta 1                                         0.92   0.15\*     -0.02                 -0.04   0.14       0.02       -0.20\*\*   -0.02
  ***Darkred* module**                                                                                                                                                         
  *FZD4*                  Frizzled class receptor 4                                          0.83   0.24\*\*   -0.03                 0.10    0.25\*\*   0.20\*\*   -0.06       0.05
  *CDC42EP2*              CDC42 effector protein 2                                           0.84   0.18\*     -0.10                 0.07    0.15       0.16\*     -0.12       0.02
  *COL15A1*               Collagen type XV alpha 1 chain                                     0.84   0.18\*     -0.03                 0.08    0.17\*     0.20\*\*   -0.08       0.00
  *TBXA2R*                Thromboxane A2 receptor                                            0.81   0.18\*     -0.05                 0.12    0.13       0.16\*     -0.02       0.04
  *EHD2*                  EH domain containing 2                                             0.89   0.16\*     -0.04                 0.04    0.18\*     0.17\*     -0.03       0.03
  *GPR124*                G-protein coupled receptor 124                                     0.89   0.16\*     0.00                  0.05    0.18\*     0.22\*\*   -0.05       0.04
  *VIM*                   Vimentin                                                           0.90   0.15\*     -0.03                 0.12    0.16\*     0.17\*     -0.05       0.04
  *EFEMP2*                EGF containing fibulin extracellular matrix protein 2              0.88   0.15\*     -0.03                 0.11    0.13       0.16\*     -0.06       0.04
  *TBX2*                  T-box 2                                                            0.83   0.12       0.02                  0.07    0.19\*     0.18\*     -0.07       0.03
  ***Gray60* module**                                                                                                                                                          
  *COL8A2*                Collagen type VIII alpha 2 chain                                   0.88   0.24\*\*   -0.11                 0.04    0.21\*\*   0.16\*     0.01        0.02
  *MATN2*                 Matrilin 2                                                         0.86   0.24\*\*   -0.09                 0.10    0.19\*     0.18\*     -0.09       -0.01
  *KANK2*                 KN motif and ankyrin repeat domains 2                              0.84   0.19\*     -0.10                 0.04    0.18\*     0.17\*     -0.05       0.01
  *COL6A1*                Collagen type VI alpha 1 chain                                     0.83   0.18\*     -0.07                 0.06    0.18\*     0.20\*\*   -0.07       0.04
  *TRPC1*                 Transient receptor potential cation channel subfamily C member 1   0.81   0.18\*     -0.19\*               0.14    0.12       0.15\*     -0.12       -0.01
  *COL16A1*               Collagen type XVI alpha 1 chain                                    0.83   0.17\*     -0.18\*               -0.02   0.13       0.17\*     -0.05       -0.04
  *COL3A1*                Collagen type III alpha 1 chain                                    0.83   0.17\*     -0.12                 0.06    0.13       0.16\*     -0.13       -0.05
  *RUNX1T1*               RUNX1 translocation partner 1                                      0.86   0.16\*     -0.02                 0.07    0.20\*\*   0.18\*     -0.05       -0.03
  *AEBP1*                 AE binding protein 1                                               0.84   0.16\*     -0.08                 0.03    0.18\*     0.16\*     -0.08       -0.08
  *COL1A1*                Collagen type I alpha 1 chain                                      0.82   0.16\*     -0.09                 0.08    0.12       0.22\*\*   -0.07       0.07
  *RGS11*                 Regulator of G-protein signaling 11                                0.81   0.13       -0.08                 0.05    0.15\*     0.24\*\*   -0.08       0.00

∗

P-value of partial correlation \< 0.05;

∗∗

P

-value of partial correlation \< 0.01; MM, module membership; BW, birth weight

.

Sensitivity Analyses
--------------------

Associations between traits of interest and MEs or hub genes were assessed after excluding non-European newborns ([Supplementary Table S6](#SM1){ref-type="supplementary-material"}), mothers with gestational diabetes ([Supplementary Table S7](#SM1){ref-type="supplementary-material"}), and mothers with gestational hypertension ([Supplementary Table S8](#SM1){ref-type="supplementary-material"}) from the analysis. Although some *P*-values for correlations with MEs became larger than 0.1, correlation coefficients changed only slightly and associations with hub genes mostly remained significant (*P* \< 0.05). The exclusion of mothers with hypertension, however, resulted in smaller and non-significant partial correlations with maternal BMI in the *darkgray* module, both for the ME as for the five hub genes.

Mediation Analyses
------------------

Finally we tested whether the identified modules and genes mediated the association between maternal pre-pregnancy BMI and newborn birth weight ([Supplementary Table S9](#SM1){ref-type="supplementary-material"}). Although the indirect (mediating) effects of MEs were not significant, many of the hub genes from the *darkred* and *gray60* modules showed some evidence for mediation (*P*-value of the indirect effect \< 0.1). The proportion of mediation (indirect effect/total effect) ranged from 8.7 to 20.2% for hub genes from the *darkred* module and from 10.3 to 17.0% for hub genes from the *gray60* module. Significant (*P* \< 0.05) mediation was observed for five of these genes: *FZD4*, *COL15A1*, *GPR124*, *COL6A1*, and *COL1A1*.

Discussion
==========

Using WGCNA as an alternative method to conventional differential gene expression analyses, we found interesting clusters of co-expressed genes and intramodular hub genes in placental tissue that were correlated with both maternal pre-pregnancy BMI and birth weight of the newborns. Identified gene modules were mainly related to the immune and vascular system, organ and tissue development, and extracellular structure organization. Mediation analyses suggested that identified genes may be on the causal pathway of the association between maternal BMI and newborn weight, with significant mediation effects observed for five of the hub genes (*FZD4*, *COL15A1*, *GPR124*, *COL6A1*, and *COL1A1*).

One of the modules (*darkgray*) was associated with maternal pre-pregnancy BMI and with low birth weight \[below the 10^th^ percentile (2643 g)\] and was enriched for genes involved in the defense response to external stimuli. In adults, excess adiposity has been linked to a reduced immune function and host defense, possibly due to the obesity-associated low-grade chronic inflammation and disturbed levels of circulating nutrients and metabolic hormones ([@B33]). Suboptimal fetal growth has been found to increase the risk of infectious disease mortality in childhood ([@B5]), and is associated with a reduced infant immune response to routine vaccination ([@B36]). Alterations to the hypothalamic--pituitary--adrenal axis, direct nutritional effects, and an impaired transfer of immunity from mother to child have been proposed as mechanisms by which prenatal nutritional exposures may have a lasting impact on the development of the immune system ([@B38]). We also found an enrichment of genes involved in myeloid cell differentiation in the *darkgray* module, suggesting that maternal BMI might alter immune function through alterations in hematopoietic cell development. In line with this, a murine model has recently shown that a maternal high fat diet restricts the expansion and renewal of fetal hematopoietic stem cells, and promotes differentiation of both lymphoid and myeloid cell lineages ([@B21]).

*AHSP*, *SLC4A1*, and *HBQ1* genes were identified as hub genes in the *darkgray* module and were positively correlated with pre-pregnancy BMI, and negatively with low birth weight. *AHSP* acts as a chaperone to prevent the harmful aggregation of alpha-hemoglobin during normal erythroid cell development. *SLC4A1* is expressed in the erythrocyte plasma membrane and functions both as a transporter that mediates electroneutral anion exchange across the cell membrane and as a structural protein. *HBQ1* is a hemoglobin gene found in human fetal erythroid tissue. Although this is the first study suggesting a role of these genes in developmental programming by maternal BMI, studies on adults have demonstrated an upregulation of these genes in association with BMI or obesity in matrices such as adipose tissue ([@B39]), whole blood (*SLC4A1*) ([@B52]), peripheral blood (*AHSP*) ([@B13]), and meniscus samples (*HBQ1*) ([@B40]). In addition, *AHSP* and *SLC4A1* expression has been found to be higher in placental tissue of large-for-gestational-age infants ([@B3]), whereas decreased placental *AHSP* mRNA levels were found in pregnancies complicated by low platelet syndrome, fetal death, and intrauterine growth restriction (although not significant for the latter) ([@B10]).

The two other identified modules (*darkred* and *gray60*) were positively correlated with maternal BMI, maternal obesity, and birth weight. The correlation between these modules (Pearson correlation between eigengenes = 0.648) is reflected in the overlap in GO terms related to tissue and organ development. The *darkred* module contained several vascular-related genes, with blood vessel morphogenesis as top GO term, and vascular smooth muscle contraction as top KEGG pathway. Alterations in placental vasculature have an impact on the exchange of nutrients and gasses between mother and fetus, thereby affecting fetal growth. Animal models suggest an increased placental nutrient transport capacity as the mechanistic link between maternal obesity and fetal overgrowth, whereas reduced vascular branching in placentas with hypertensive disorders such as preeclampsia may be an underlying mechanism restricting fetal growth in obese pregnancies ([@B17]). In a RNA-sequencing study on placenta from 24 subjects, maternal obesity increased markers of inflammation and oxidative stress and decreased regulators of angiogenesis (HIF-1α and VEGF-A) ([@B42]). In a mouse model, however, maternal placental HIF-1α protein was elevated by maternal obesity ([@B11]), supporting the hypothesis that obesity during pregnancy is associated with placental hypoxia, resulting in an induction of angiogenesis to enhance fetoplacental vascular growth ([@B9]).

Consistent with the functional enrichment analyses, we identified hub genes related to blood vessel morphogenesis in the *darkred* module: *TBXA2R*, *FZD4*, *COL15A1*, and *TBX2* were positively associated with maternal BMI and/or obesity and with birth weight. *TBXA2R* is the receptor for Thromboxane A2 (*TXA2*), a marker of platelet activation that is greater in obese than in lean subjects ([@B14]). In line with this is the upregulation of adipose tissue *TBXA2R* in obese mice, with genetic models suggesting a role for *TXA2* in modulating peripheral tissue insulin sensitivity and adipose tissue fibrosis ([@B28]). The role of *TBXA2R* in obese pregnancies, however, is still unclear. It has recently been suggested that an impaired vasoconstriction and vasodilatation in myometrial arteries from obese women may be linked to increased *TX2A* levels, although *TBXA2R* expression in endothelial and smooth muscle cells was not affected by maternal BMI in that study ([@B15]). *FZD4*, a member of the frizzled gene family, encodes a protein that acts as a receptor for wingless (Wnt) proteins and plays an important role in retinal vascularization. In male adults, hyperinsulinemia was found to be associated with a decreased expression of Wnt signaling genes (including *FZD4*) in adipose tissue, while expression was increased in skeletal muscle, which might reflect a compensatory mechanism to increase muscle glucose uptake and to generate new fat cells ([@B22]). Another hub gene related to blood vessel morphogenesis, *TBX2*, is implicated in developmental processes such as cell fate regulation, tissue and organ morphogenesis ([@B2]). An upregulation of this gene in association with BMI in adults has been demonstrated ([@B52]), but the importance of this gene in fetal metabolic programming needs further investigation.

Other identified hub genes in the *darkred* module were *EHD2*, *CDC42EP2*, *GPR124*, *VIM*, and *EFEMP2*. *EHD2* functions in membrane trafficking between the plasma membrane and endosomes, and has been associated with obesity in mice models ([@B47]). *CDC42EP2* and *VIM* are involved in maintaining cell shape and integrity by stabilizing cytoskeletal interactions. VIM expression in islet cells is higher in type 2 diabetes ([@B41]), although VIM protein levels were lower in placenta from obese pregnant women with normal glucose tolerance ([@B37]). *GPR124* controls central nervous system angiogenesis and blood--brain barrier integrity by promoting canonical Wnt signaling via *FZD4* ([@B56]). A recent study in mice suggests that maternal obesity during pregnancy increases the permeability of the blood--brain barrier, which might affect the postnatal development of the hypothalamic circuits that regulate body weight through excessive exposure to factors such as leptin or ghrelin ([@B23]). Lastly, the *EFEMP2* gene is implicated in blood coagulation, activation of complement and determination of cell fate during development, and has been reported to be upregulated in adipose tissue of mice ([@B34]).

In line with our findings for the *gray60* module, the PI3K-Akt signaling and focal adhesion pathways were found to be upregulated in the placenta of non-diabetic macrosomia ([@B46]). Altered maternal nutrient partitioning and placental upregulation of metabolic signaling pathways, including PI3K, have also been observed in obese mice ([@B44]). Extracellular structure organization was the most enriched biological process in the *gray60* module. The extracellular matrix (ECM) plays a crucial role in adipocyte development and function. Instability of the ECM may be a direct consequence of adipocyte overgrowth, or may indirectly result from obesity-associated hypoxia ([@B31]). Several studies have reported an increase in gene expression of collagens, growth factors, and enzymatic regulators of the skeletal muscle ECM in obesity ([@B32]). In line with this, maternal obesity has been found to enhance collagen accumulation and cross-linking in skeletal muscle of ovine offspring ([@B18]). Although this is the first study to report an upregulation of collagen genes in association with maternal BMI in the placenta, a thickening of the trophoblastic basement membrane with increasing amounts of collagen has been demonstrated in the context of maternal diabetes ([@B50]). In pre-eclamptic placentas, collagen genes have been found to be downregulated ([@B16]).

An advantage of our data analysis approach is that WGCNA is a method that takes into account the correlation between genes. WGCNA clusters highly co-expressed genes into modules of conserved biological function ([@B55]). In addition, it quantifies the extent to which genes share the same neighbors, allowing the identification of highly connected genes inside each module. Because of their key position inside the network, such hub genes are likely to be biomarkers of a specific phenotype or disease status. Another strength of this study is the availability of placental microarray data from a relatively large study population that is representative for the gestational segment of the population at large ([@B19]). In contrast to typical transcriptome studies contrasting an often limited number of adverse (e.g., obese or macrosomic) and normal phenotypes, our study results reflect normal variations in maternal and newborn traits. However, a small variation in phenotypic traits is likely to result in rather modest differences in gene expression, which may explain the absence of significant differentially expressed genes after multiple testing correction in the univariate models. Nevertheless, using a co-expression analysis, we were able to pick up dysregulated gene networks and hub genes associated with such subtle differences in maternal BMI and newborn weight. By focusing on groups of coordinately expressed genes, WGCNA has the advantage of heavily reducing the number of multiple comparisons and providing a functional interpretation that is biologically significant.

As in all epidemiological studies, findings of this study do not necessarily reflect causal associations. Observed alterations in expression of some genes may be due to confounding factors that also correlate with transcript variability. However, in contrast to most studies using WGCNA, associations between expression levels (of modules and genes) and phenotypic traits were corrected for potential confounders such as ethnicity, maternal smoking, and gestational weight gain. In addition, the placenta represents a heterogeneous mixture of cells and expression levels are expected to vary between cell types. Although biopsies were taken at a fixed location at the fetal side using a standardized sampling method, residual confounding by cell composition cannot be ruled out completely. Finally, associations observed between low birth weight and (hub genes inside) the *darkgray* module should be interpreted with caution because of the low number (*n* = 19) of observations inside the low birth weight category.

Conclusion
==========

Using a co-expression approach, we identified pivotal placental gene clusters that may shed new light on the molecular link between maternal and offspring metabolic health. Interestingly, this study indicated genes involved in immune defense and erythrocyte-related hub genes to be upregulated in association with maternal pre-pregnancy BMI and downregulated in association with low birth weight. Moreover, modules enriched for developmental, vascular, and extracellular matrix-related genes were positively correlated with maternal BMI and birth weight. Given the critical role of the placenta in regulating gestational development and the intrauterine environment, the identified gene networks may reflect molecular mechanisms underlying placental dysfunction associated with BMI and may be involved in fetal metabolic programming.
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